^
    4ms
    A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Changchun GeneScience Pharmaceutical Co., Ltd.
    New P2 trial
    |
    genakumab (Gensci048)
    almost2years
    Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=120, Recruiting, GeneScience Pharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL1B (Interleukin 1, beta) • CRP (C-reactive protein)
    |
    Tevimbra (tislelizumab) • genakumab (Gensci048)
    almost2years
    Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=120, Not yet recruiting, GeneScience Pharmaceuticals Co., Ltd.
    New P1 trial • Combination therapy
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL1B (Interleukin 1, beta) • CRP (C-reactive protein)
    |
    Tevimbra (tislelizumab) • genakumab (Gensci048)